On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46. The U.S. drugmaker reported sales of $13.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of $13.02 billion. Truist Securities sees the strong demand growth as highly encouraging and, at current levels, Pfizer shares are very attractive given the company’s diverse portfolio that is gaining momentum, effective cost-cutting initiatives, and a commitment to maintaining or growing an attractive dividend. The analyst maintains the Buy rating, with a price target of $36. Goldman Sachs notes that Pfizer’s performance included noteworthy standouts (Vyndaqel, Nurtec) and evidence that integration of the Seagen acquisition is progressing well. Goldman ...